EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGF-R POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Tough-to-Treat cancers in brain and lungs
Disease control OngoingThis study is testing an oral medication called BDTX-1535 for adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor) that have specific genetic changes. The goal is to find the safest and most effective dose and see if the drug can shrink tumors, …
Matched conditions: EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Targeted attack on rare lung cancer mutations
Disease control OngoingThis study is testing a drug called dacomitinib for people with advanced non-small cell lung cancer who have specific, less common genetic mutations in their tumors. It aims to see how well the drug controls the cancer and how safe it is. About 30 participants will take the oral …
Matched conditions: EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC